机构：[1]School of Pharmaceutical Sciences (Shenzhen), Sun Yat-sen University, Shenzhen, China.深圳医学信息中心中国医学科学院阜外医院深圳医院[2]Guangdong Provincial Key Laboratory of New Drug Design and Evaluation, Guangdong Province Engineering Laboratoty for Druggability and New Drug Evaluation, School of Pharmaceutical Sciences, Sun Yat-sen University, Guangzhou, China.[3]Guangdong Lung Cancer Institute, Guangdong Provincial Key Laboratory of Translational Medicine in Lung Cancer, Guangdong Provincial People's Hospital and Guangdong Academy of Medical Sciences, Guangzhou, China.广东省人民医院[4]Institute of Marine Drugs, Guangxi University of Chinese Medicine, Nanning, China.[5]CAS Key Laboratory of Tropical Marine Bio-resources and Ecology/Guangdong Key Laboratory of Marine Materia Medica, South China Sea Institute of Oceanology, Chinese Academy of Sciences, Guangzhou, China.[6]National-Local Joint Engineering Laboratory of Druggability and New Drugs Evaluation, Sun Yat-sen University, Guangzhou, China.
Small cell lung cancer (SCLC) was defined as a recalcitrant cancer, and novel therapies are urgently needed. Marine natural products (MNPs) may bring continuing hope for treatment of SCLC. In this study, 3-bromoascochlorin (BAS), an MNP isolated from the coral-derived fungus Acremonium sclerotigenum GXIMD 02501, was primarily screened out with antiproliferative activity towards SCLC cell lines. Then western blot analysis (WB) and flow cytometry were conducted, and we found BAS could induce the apoptosis of H446 and H69AR cells. Besides, BAS could suppress the invasion and migration of H446. In an SCLC xenograft mice model, BAS inhibited the growth of tumor without affecting the body weight of mice. Finally, the underlying mechanisms were preliminarily explored. According to the results of RNA-seq, reverse transcription-quantitative polymerase chain reaction, and WB, our results revealed that BAS exerted antitumor activity via inhibiting mitogen-activated protein kinase (MAPK)/extracellular signal-regulated kinases (ERK) pathway. Collectively, these results indicated that BAS can be used as a promising compound for the treatment of human SCLC
基金：
Funding information
High‐level Hospital Construction Project,
Grant/Award Number: DFJH201917;
Key‐Area Research and Development Program
第一作者机构：[1]School of Pharmaceutical Sciences (Shenzhen), Sun Yat-sen University, Shenzhen, China.
共同第一作者：
通讯作者：
通讯机构：[2]Guangdong Provincial Key Laboratory of New Drug Design and Evaluation, Guangdong Province Engineering Laboratoty for Druggability and New Drug Evaluation, School of Pharmaceutical Sciences, Sun Yat-sen University, Guangzhou, China.[3]Guangdong Lung Cancer Institute, Guangdong Provincial Key Laboratory of Translational Medicine in Lung Cancer, Guangdong Provincial People's Hospital and Guangdong Academy of Medical Sciences, Guangzhou, China.[4]Institute of Marine Drugs, Guangxi University of Chinese Medicine, Nanning, China.[6]National-Local Joint Engineering Laboratory of Druggability and New Drugs Evaluation, Sun Yat-sen University, Guangzhou, China.[*1]Institute of Marine Drugs, Guangxi University of Chinese Medicine, 530200 Nanning, China.[*2]Guangdong Lung Cancer Institute, Guangdong Provincial Key Laboratory of Translational Medicine in Lung Cancer, Guangdong Provincial People's Hospital and Guangdong Academy of Medical Sciences, 510080 Guangzhou, China.[*3]Guangdong Provincial Key Laboratory of New Drug Design and Evaluation, Guangdong Province Engineering Laboratoty for Druggability and New Drug Evaluation, School of Pharmaceutical Sciences, Sun Yat‐sen University, 510006 Guangzhou, China.
推荐引用方式(GB/T 7714)：
Zhang Zhenhua,Zhang Yidi,Yang Chunju,et al.Antitumor effects of 3-bromoascochlorin on small cell lung cancer via inhibiting MAPK pathway.[J].CELL BIOLOGY INTERNATIONAL.2021,45(11):2380-2390.doi:10.1002/cbin.11674.
APA：
Zhang Zhenhua,Zhang Yidi,Yang Chunju,Wang Qianyu,Wang Hong...&Wang Junjian.(2021).Antitumor effects of 3-bromoascochlorin on small cell lung cancer via inhibiting MAPK pathway..CELL BIOLOGY INTERNATIONAL,45,(11)
MLA：
Zhang Zhenhua,et al."Antitumor effects of 3-bromoascochlorin on small cell lung cancer via inhibiting MAPK pathway.".CELL BIOLOGY INTERNATIONAL 45..11(2021):2380-2390
